MERCK & CO Aktie

 

Merck & Co., Inc. (NYSE:MRK) has been on a strong recovery run, gaining 23% over the past year and 8% year-to-date, though the stock has pulled back some, now well below its 52-week high of $125.14. Most analysts hold measured views, with Street consensus sitting at $127.22. But Wells Fargo sees considerably more upside, raising ... Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150 The post Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150 appeared first on 24/7 Wall St.....

The latest trading day saw Merck (MRK) settling at $117.11, representing a +1.14% change from its previous close....

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

MRK's Keytruda posted $31.7B in 2025 sales. Can new approvals, ongoing studies and a revamped structure keep oncology growth strong through 2026?...

In the latest trading session, Merck (MRK) closed at $121.41, marking a -1.95% move from the previous day....

The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?...

Merck & Co. is cutting staff at a US plant that makes its HPV vaccine Gardasil amid a decrease in global demand for the cancer-preventing shot....

A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a neutral 43 this week. The catalyst is Merck's February 23 announcement to split its Human Health business into two divisions: one ... Merck Stock Jumps But Reddit Traders Are Getting Cold Feet The post Merck Stock Jumps But Reddit Traders Are Getting Cold Feet appeared first on 24/7 Wall St.....

Das Krebsmedikament Keytruda von Merck & Co ist die umsatzstärkste verschreibungspflichtige Arznei der Welt – Mercks Patent darauf läuft 2030 aus. Um davon nicht kalt erwischt zu werden, baut der Pharmakonzern sein Geschäft um....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

KENILWORTH (NJ) (dpa-AFX) - Merck & Co., Inc. (MRK), Monday announced its plan to organize its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Bu......

Pharma - Der US-Konzern Merck & Co spaltet seine Pharmasparte auf....

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human Health Business Unit structure, Jannie Oosthuizen has been appointed executive vice president and president, Oncology and MSD International. Oosthuizen most recently served as senior vice president and president, Merck Human Health U.S., where he oversaw P&L, strategy and commercialization for ...

Merck & Co. plans to split its main pharmaceutical unit in two as it prepares for the approaching patent expiry of its best-selling drug, according to the Wall Street Journal....

BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor....

MRK outlines solid long-term outlook with more than $70B opportunity beyond Keytruda LOE, backed by pipeline progress, new product launches and M&A deals....

Merck stock has risen more than 7% in a month on a stronger long-term outlook, but 2026 headwinds, Keytruda patent risk and Gardasil slump keep it a Sell....

Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?...

Guindo, Chirfi - Vorstand - Tag der Transaktion: 2026-02-12...

KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) on Wednesday said the U.S. Food and Drug Administration has approved Keytruda and Keytruda Qlx, a subcutaneous formulation of Keytruda, in combina......